The acquisition takes place two months after G1 Therapeutics' lung cancer drug Cosela failed in a phase III trial, where the drug was tested as a treatment against breast cancer. The negative news led to cutbacks and a stock market backlash for the company, which was also forced to reduce its workforce by 30 percent the year before after negative s...